CINACALCET HYDROCHLORIDE (cinacalcet hydrochloride) by Teva is calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of pth synthesis and secretion. Approved for secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies ( )], hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies ( )], hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels and 1 more indications. First approved in 2018.
Drug data last refreshed 21h ago
calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, is a calcimimetic agent that directly lowers PTH levels by increasing the sensitivity of the calcium-sensing…
Worked on CINACALCET HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events